Published in J Hum Hypertens on August 01, 1997
Sex differences in primary hypertension. Biol Sex Differ (2012) 1.37
Blood pressure and ageing. Postgrad Med J (2007) 1.29
Gender-specific differences in the kinetics of nonfasting TRL, IDL, and LDL apolipoprotein B-100 in men and premenopausal women. Arterioscler Thromb Vasc Biol (2008) 0.88
Cardiovascular hemodynamics during stress in premenopausal versus postmenopausal women. Menopause (2010) 0.88
Hypertension and aging. Ageing Res Rev (2016) 0.84
Plasma lactate and incident hypertension in the atherosclerosis risk in communities study. Am J Hypertens (2014) 0.83
Sex-specific immune modulation of primary hypertension. Cell Immunol (2014) 0.81
Administration of 17β-estradiol to ovariectomized obese female mice reverses obesity-hypertension through an ACE2-dependent mechanism. Am J Physiol Endocrinol Metab (2015) 0.80
Gender differences in the association between serum γ-glutamyltransferase and blood pressure change: a prospective community-based cohort study. J Korean Med Sci (2014) 0.80
Caffeine and blood pressure response: sex, age, and hormonal status. J Womens Health (Larchmt) (2010) 0.79
Difference in blood pressure between early and late menopausal transition was significant in healthy Korean women. BMC Womens Health (2015) 0.78
Pulse pressure and age at menopause. BMC Womens Health (2002) 0.78
Prevalence and Associated Factors of Hypertension: A Community-Based Cross-Sectional Study in Municipalities of Kathmandu, Nepal. Int J Hypertens (2016) 0.77
A routine biomarker-based risk prediction model for metabolic syndrome in urban Han Chinese population. BMC Public Health (2015) 0.76
Is immune system-related hypertension associated with ovarian hormone deficiency? Exp Physiol (2015) 0.75
Autonomic control of cardiovascular system in pre- and postmenopausal women: a cross-sectional study. J Turk Ger Gynecol Assoc (2015) 0.75
Height and sex is strongly associated with radial augmentation index in Korean patients with never-treated hypertension. Clin Interv Aging (2016) 0.75
Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet (1985) 8.35
Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet (1998) 6.20
Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet (2001) 6.05
The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a prospective, multicentre study. Working Group on Sepsis related Problems of the ESICM. Intensive Care Med (1999) 3.93
Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA Group. Lancet (1999) 3.81
Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med (1999) 3.43
Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol (2005) 3.34
Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet (2000) 3.25
Glucose intolerance during diuretic therapy. Results of trial by the European Working Party on Hypertension in the Elderly. Lancet (1978) 2.56
Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet (1986) 2.50
Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Intern Med (1997) 2.40
Renal function, cytogenetic measurements, and sexual development in adolescents in relation to environmental pollutants: a feasibility study of biomarkers. Lancet (2001) 2.13
Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med (1994) 2.12
Reference values for self-recorded blood pressure: a meta-analysis of summary data. Arch Intern Med (1998) 2.01
Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med (2000) 1.99
Response to antihypertensive therapy in older patients with sustained and nonsustained systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Circulation (2000) 1.98
Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol, and organization. Aging (Milano) (1991) 1.93
Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens (2003) 1.93
Nocturnal blood pressure fall on ambulatory monitoring in a large international database. The "Ad Hoc' Working Group. Hypertension (1997) 1.90
Bradycardia, ventricular pauses, syncope, and sports. Lancet (1984) 1.77
The protein tyrosine kinase p56lck inhibits CD4 endocytosis by preventing entry of CD4 into coated pits. J Cell Biol (1992) 1.67
Anthropometry, carbohydrate and lipid metabolism in the East Flanders Prospective Twin Survey: heritabilities. Diabetologia (2007) 1.56
Ossification timing of sacral vertebrae by ultrasound in the mid-second trimester of pregnancy. Prenat Diagn (2003) 1.55
Beta-blockers: once or three times a day? Br Med J (1978) 1.54
Isolated systolic hypertension in the elderly. J Hypertens (1990) 1.48
The relationships between left ventricular mass and daytime and night-time blood pressures: a meta-analysis of comparative studies. J Hypertens (1995) 1.45
Human immunodeficiency virus gp120 and derived peptides activate protein tyrosine kinase p56lck in human CD4 T lymphocytes. Eur J Immunol (1993) 1.42
Night-day blood pressure ratio and dipping pattern as predictors of death and cardiovascular events in hypertension. J Hum Hypertens (2009) 1.42
[Hemodynamic effects of urapidil in men]. Presse Med (1990) 1.41
An epidemiological re-appraisal of the association between blood pressure and blood lead: a meta-analysis. J Hum Hypertens (2002) 1.40
Salt intake and blood pressure in the general population: a controlled intervention trial in two towns. J Hypertens (1988) 1.39
Captopril and agranulocytosis. Lancet (1980) 1.36
Blood pressure and urinary cations in urban Bantu of Zaire. Am J Epidemiol (1986) 1.30
Effects of three candidate genes on prevalence and incidence of hypertension in a Caucasian population. J Hypertens (2001) 1.30
Noninvasive assessment of seasonal variations in cardiac structure and function in cyclists. Circulation (1983) 1.29
The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk. J Hypertens (1997) 1.27
Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol (1981) 1.26
A meta-analysis of outcome trials in elderly hypertensives. J Hypertens (1992) 1.26
Exposure to cadmium and conventional and ambulatory blood pressures in a prospective population study. Public Health and Environmental Exposure to Cadmium Study Group. Am J Hypertens (2000) 1.26
Unexpected effects of coffee consumption on liver enzymes. Eur J Epidemiol (1993) 1.25
Multiple standardized clinic blood pressures may predict left ventricular mass as well as ambulatory monitoring. A metaanalysis of comparative studies. Am J Hypertens (1995) 1.23
Urinary cadmium and lead concentrations and their relation to blood pressure in a population with low exposure. Br J Ind Med (1984) 1.20
Prognostic significance of peak exercise capacity in patients with coronary artery disease. J Am Coll Cardiol (1994) 1.20
Modern approaches to blood pressure measurement. Occup Environ Med (2000) 1.19
Birth weight and body composition in young adult men--a prospective twin study. Int J Obes Relat Metab Disord (2001) 1.19
Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. Ann Oncol (2005) 1.18
The relationship between body weight and blood pressure. J Hum Hypertens (1988) 1.15
Four urinary cations and blood pressure. A population study in two Belgian towns. Am J Epidemiol (1983) 1.14
The influence of menopause on blood pressure. J Hum Hypertens (1989) 1.13
Blood Pressure Monitoring. Task force III: Target-organ damage, morbidity and mortality. Blood Press Monit (1999) 1.13
Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents. Cell Death Differ (2007) 1.13
High pp60c-src level in human platelet dense bodies. Blood (1989) 1.11
Haemodynamic and humoral responses to chronic ketanserin treatment in essential hypertension. Br Heart J (1984) 1.11
Mean and range of the ambulatory pressure in normotensive subjects from a meta-analysis of 23 studies. Am J Cardiol (1991) 1.11
INDANA: a meta-analysis on individual patient data in hypertension. Protocol and preliminary results. Therapie (1995) 1.10
Cardiac structure and function in cyclists and runners. Comparative echocardiographic study. Br Heart J (1984) 1.09
Should exercise blood pressure be measured in clinical practice? J Hypertens (1998) 1.08
Secondary prevention with beta-adrenoceptor blockers in post-myocardial infarction patients. Am Heart J (1982) 1.08
Relationship between phosphorylation and activity of heme-regulated eukaryotic initiation factor 2 alpha kinase. Proc Natl Acad Sci U S A (1981) 1.07
Health effects of environmental exposure to cadmium: objectives, design and organization of the Cadmibel Study: a cross-sectional morbidity study carried out in Belgium from 1985 to 1989. Environ Health Perspect (1990) 1.07
Prognostic value of training-induced change in peak exercise capacity in patients with myocardial infarcts and patients with coronary bypass surgery. Am J Cardiol (1995) 1.06
The pulse pressure-to-stroke index ratio predicts cardiovascular events and death in uncomplicated hypertension. J Am Coll Cardiol (2001) 1.06
Salt and blood pressure in Belgium. J Epidemiol Community Health (1981) 1.06
Lack of influence of menopause on blood pressure and cardiovascular risk profile: a 16-year longitudinal study concerning a cohort of 568 women. J Hypertens (1996) 1.06
Treatment with beta-blockers for the primary prevention of the cardiovascular complications of hypertension. Eur Heart J (1999) 1.05
ESH-ESC guidelines for the management of hypertension. Herz (2006) 1.05
Advantages and disadvantages of the meta-analysis approach. J Hypertens Suppl (1996) 1.05
Independent prognostic value of the ambulatory arterial stiffness index and aortic pulse wave velocity in a general population. J Hum Hypertens (2007) 1.04
Both T cell receptor (TcR)-CD3 complex and CD2 increase the tyrosine kinase activity of p56lck. CD2 can mediate TcR-CD3-independent and CD45-dependent activation of p56lck. Eur J Immunol (1992) 1.04
Prediction of the actual awake and asleep blood pressures by various methods of 24 h pressure analysis. J Hypertens (1996) 1.04
The international database of self-recorded blood pressures in normotensive and untreated hypertensive subjects. Blood Press Monit (1999) 1.03
Public health implications of environmental exposure to cadmium and lead: an overview of epidemiological studies in Belgium. Working Groups. J Cardiovasc Risk (1996) 1.03
Effect of two different therapeutic approaches on total and cardiovascular mortality in a Cardiovascular Study in the Elderly (CASTEL). Jpn Heart J (1994) 1.03
The inheritance of left ventricular structure and function assessed by imaging and Doppler echocardiography. Am Heart J (1991) 1.03
The diurnal blood pressure profile. A population study. Am J Hypertens (1992) 1.02
Rapid activation and nuclear translocation of mitogen-activated protein kinases in response to physiological concentration of glucose in the MIN6 pancreatic beta cell line. J Biol Chem (1998) 1.02
Mechanism of hypotensive effect during betaadrenergic blockade in hypertensive patients. Am Heart J (1976) 1.02
Letter: Beta receptors and renin release. N Engl J Med (1974) 1.02